M&A
confidence high
sentiment positive
materiality 0.85
cbdMD to acquire Twinlab brands; expects ~$30M combined revenue, up ~40%
cbdMD, Inc.
- Deal: assumes ~$1.75M debt, issues 2,229,805 shares (19.9% of outstanding) to secured creditor; court approval required.
- Acquires Twinlab, Reserveage, Metabolife, Alvita Tea brands; expands into supplements, sports nutrition, beauty, weight loss, longevity.
- Combined trailing 12-month revenue ending June 2026 ~$30M, ~40% above cbdMD standalone; incremental revenue expected positive contribution.
- Also amended Series B preferred conversion price from $1.00 to $0.60 per share, effective Sept 2, 2026; 591,207 shares outstanding.